Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC ...

Tuesday, the European Commission approved Roche Holdings AG’s (OTC:RHHBY) Tecentriq SC (atezolizumab), the European Union (EU) ‘s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) ...

Basel, 13 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq HybrezaTM (atezolizumab and hyaluronidase-tqjs), ...

Ocrevus Zunovo is the first and only biannual professional-administered ~10 min SC injection approved for both forms of multiple sclerosis. The subcutaneous formulation of Tecentriq received its first ...

It’s looking like Roche may not receive an on-time FDA decision for the subcutaneous version of its cancer immunotherapy Tecentriq. The FDA was supposed to dole out a verdict on subcutaneous Tecentriq ...

(RTTNews) - Roche (RHHBY) announced the European Commission has granted marketing authorisation for Tecentriq SC, a PD-L1 cancer immunotherapy for subcutaneous injection. The authorisation applies to ...

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of Tecentriq ® SC ...

Multiple oncology studies suggest that most cancer patients prefer to receive their treatments via subcutaneous delivery, instead of intravenous infusion because of reduced discomfort, ease of ...

Cancer patients often spend hours in hospitals receiving conventional chemotherapies or immunotherapies â often offered as first-line treatment following diagnosis of various malignancies. Swiss-based ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This CMI is for the subcutaneous dosage form of Tecentriq. For ...

– Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous (IV) Tecentriq – – New subcutaneous (SC ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...